Previous studies with these and other SGLT2 inhibitors in patients with type 2 diabetes demonstrated significant cardiovascular benefits (EMPA‐REG (Empagliflozin) Cardiovascular Outcome), DECLARE‐TIMI 58 (Dapagliflozin Effect on Cardiovascular Events–Thrombolysis in Myocardial Infarction 58), and CANVAS (Canagliflozin Cardiovascular Assessment Study).2, 3, 4. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.